原发性胶质肉瘤患者的预后因素:一项单中心回顾性研究
该单中心回顾性研究纳入2011年3月至2023年6月唐都医院诊断为胶质肉瘤的77例患者,中位年龄57岁(范围13-83岁)。多因素分析显示完整切除、年龄≤65岁、接受Stupp方案治疗及复发后积极治疗是总生存的独立预测因素。作者认为最佳管理为最大安全切除联合替莫唑胺放化疗,复发时行挽救治疗,并需监测转移风险。
要点
- 完整切除、年龄≤65岁、Stupp方案及复发后积极治疗是总生存独立预测因素。
- 单因素分析中Ki67≤25%、术后KPS≥70与生存改善相关。
- 治疗期间需仔细监测转移风险,1例出现皮下转移。
核心结论
- 作者认为原发性胶质肉瘤的最佳管理包括最大安全切除联合替莫唑胺辅助放化疗,复发时行挽救治疗,治疗过程中应仔细监测转移风险。
研究设计与样本
- 单中心回顾性分析2011年3月至2023年6月唐都医院诊断为胶质肉瘤患者的病历资料,排除既往胶质瘤史或接受术前放化疗者,最终纳入77例,采用Kaplan-Meier和Cox回归进行生存分析。
主要发现
- 最终分析共纳入77例患者,中位年龄57岁(范围13-83岁),最常见首发症状为头痛,最常受累部位为颞叶。
- 单因素分析显示年龄≤65岁、完整切除、Ki67≤25%、术后Karnofsky功能状态评分≥70、遵循Stupp方案及复发时接受额外积极治疗与生存改善相关。
- 多因素分析确定完整切除、年龄≤65岁、Stupp方案治疗及复发后积极治疗为总生存的独立预测因素。
- 治疗期间有1例患者出现皮下转移。
临床怎么用
- 作者认为最佳管理为最大安全切除联合替莫唑胺辅助放化疗,复发时行挽救治疗,并密切监测转移风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary gliosarcoma is a rare form of malignant central nervous system tumor, with limited understanding regarding its prognostic determinants and effective therapeutic interventions. METHODS: The medical records of patients diagnosed with gliosarcoma at Tangdu Hospital between March 2011 and June 2023 were retrospectively analyzed in this study. Patients with a prior history of glioma or those who received preoperative chemoradiotherapy were excluded. Survival analyses were conducted using Kaplan-Meier and Cox regression analysis. RESULTS: A total of 77 patients were included in the final analysis, with a median age of 57 years (range: 13-83). The predominant symptom leading to diagnosis was headache, and the temporal lobe was the most frequently affected site. Univariate analysis revealed that age ≤65 years, complete resection, Ki67 ≤ 25%, postoperative Karnofsky Performance Status ≥ 70, adherence to the Stupp protocol, and additional active therapy upon relapse were associated with enhanced survival. Furthermore, multivariate analysis identified complete resection, age ≤65 years, Stupp protocol treatment, and active therapy following relapse were independent predictors of overall survival. Notably, 1 patient experienced subcutaneous metastasis during treatment. CONCLUSIONS: The present study's findings suggest that optimal management of primary gliosarcoma entails maximal safe resection, combined with adjuvant radiotherapy and chemotherapy with temozolomide, followed by salvage therapy in case of recurrence. However, the risk of metastases should be carefully monitored during the treatment course.
引用
- Li C, Zhou W, Wang P, et al. Prognostic Factors for Patients with Primary Gliosarcoma: A Single-Center Retrospective Study. World Neurosurg. 2024. PMID: 39216722. doi:10.1016/j.wneu.2024.08.128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。